Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

KEYNOTE-826: Pembrolizumab + chemo +/- bevacizumab improves PFS and OS in East Asians with cervical cancer
24 Jul 2025
bởiNatalia Reoutova
The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) in East Asian patients with persistent, recurrent or metastatic cervical cancer, according to an exploratory analysis of the final results from the phase III KEYNOTE-826 trial.